Statin treatment alters serum n-3 to n-6 polyunsaturated fatty acids ratio in patients with dyslipidemia

Lipids in Health and Disease

Ichiro Michishita¹  Tsuyoshi Nozue¹ 

[1] Division of Cardiology, Department of Internal Medicine, Yokohama Sakae Kyosai Hospital, Federation of National Public Service Personnel Mutual Associations, 132 Katsura-cho, Sakae-ku, Yokohama 247-8581, Japan

关键词: Polyunsaturated fatty acids;    Statin;    Eicosapentaenoic acid;    Docosahexaenoic acid;   

Others  :  1217992
DOI  :  10.1186/s12944-015-0066-6

 received in 2015-06-02, accepted in 2015-06-24,  发布年份 2015

【 摘 要 】

Background

The effects of statins on serum n-3 to n-6 polyunsaturated fatty acids (PUFAs) levels have not been fully evaluated. We examined the effects of two types of statins (rosuvastatin and pitavastatin) on serum PUFAs levels and their ratios in patients with dyslipidemia.

Findings

A total of 46 patients who were not receiving lipid-lowering therapy were randomly assigned to receive either 2.5 mg/day of rosuvastatin or 2 mg/day of pitavastatin. Serum PUFAs levels were measured at baseline, at 4 weeks, and at 12 weeks. Rosuvastatin was used to treat 23 patients, and the remaining 23 patients were treated using pitavastatin. Serum docosahexaenoic acid (DHA) levels decreased significantly at 12 weeks in both groups (rosuvastatin: from 169.6 to 136.3 μg/mL, p = 0.006; pitavastatin: from 188.6 to 153.9 μg/mL, p = 0.03). However, serum levels of eicosapentaenoic acid (EPA) and arachidonic acid (AA) did not change. In addition, the EPA/AA ratio did not change, whereas the DHA/AA ratio decreased significantly at 12 weeks in both groups (rosuvastatin: from 0.99 to 0.80, p = 0.01; pitavastatin: from 1.14 to 0.91, p = 0.003). No adverse events were observed during the study period.

Conclusions

In this small, open-label, pilot study, rosuvastatin and pitavastatin decreased serum DHA levels and the DHA/AA ratio in patients with dyslipidemia.

【 授权许可】

   
2015 Nozue and Michishita.

【 参考文献 】

• [1]Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R et al.. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004; 350:1495-504.
• [2]LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC et al.. Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005; 352:1425-35.
• [3]Ridker PM, Genest J, Boekholdt SM, Libby P, Gotto AM, Nordestgaard BG et al.. JUPITER Trial Study Group. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet. 2010; 376:333-9.
• [4]Das UN. Essential fatty acids as possible mediators of the actions of statins. Prostaglandins Leukot Essent Fatty Acids. 2001; 65:37-40.
• [5]Nozue T, Yamamoto S, Tohyama S, Fukui K, Umezawa S, Onishi Y et al.. Effects of serum n-3 to n-6 polyunsaturated fatty acids ratios on coronary atherosclerosis in statin-treated patients with coronary artery disease. Am J Cardiol. 2013; 111:6-11.
• [6]Nozue T, Yamamoto S, Tohyama S, Fukui K, Umezawa S, Onishi Y et al.. Effects of statins on serum n-3 to n-6 polyunsaturated fatty acid ratios in patients with coronary artery disease. J Cardiovasc Pharmacol Ther. 2013; 18:320-6.
• [7]Nakamura N, Hamazaki T, Ohta M, Okuda K, Urakaze M, Sawazaki S et al.. Joint effects of HMG-CoA reductase inhibitors and eicosapentaenoic acids on serum lipid profile and plasma fatty acid concentrations in patients with hyperlipidemia. Int J Clin Lab Res. 1999; 29:22-5.
• [8]Harris JI, Hibbeln JR, Mackey RH, Muldoon MF. Statin treatment alters serum n-3 and n-6 fatty acids in hypercholesterolemic patients. Prostaglandins Leukot Essent Fatty Acids. 2004; 71:263-9.
• [9]Shimano H, Arai H, Harada-Shiba M, Ueshima H, Ohta T, Yamashita S et al.. Proposed guidelines for hypertriglyceridemia in Japan with non-HDL cholesterol as the second target. J Atheroscler Thromb. 2008; 15:116-21.
• [10]Igel M, Sudhop T, von Bergmann K. Pharmacology of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins), including rosuvastatin and pitavastatin. J Clin Pharmacol. 2002; 42:835-45.
• [11]Hayashi T, Yokote K, Saito Y, Iguchi A. Pitavastatin: efficacy and safety in intensive lipid lowering. Expert Opin Pharmacother. 2007; 8:2315-27.
• [12]Kurisu S, Ishibashi K, Kato Y, Mitsuba N, Dohi Y, Nishioka K et al.. Effects of lipid-lowering therapy with strong statin on serum polyunsaturated fatty acid levels in patients with coronary artery disease. Heart Vessels. 2013; 28:34-8.
• [13]Jula A, Marniemi J, Rönnemaa T, Virtanen A, Huupponen R. Effects of diet and simvastatin on fatty acid composition in hypercholesterolemic men: a randomized controlled trial. Arterioscler Thromb Vasc Biol. 2005; 25:1952-9.
• [14]Das UN. Beneficial actions of statins in the reduction of atrial fibrillation and stabilization and regression of coronary plaques: but how and why? Circ J. 2011; 75:224-5.
• [15]Das UN. Regarding the article: Hepatic ischemia/reperfusion injury is diminished by atorvastatin in Wistar rats. Arch Med Res. 2014; 45:439-40.
• [16]Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y et al.. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007; 369:1090-8.
• [17]Saito Y, Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Ishikawa Y et al.. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis. 2008; 200:135-40.
• [18]Matsuzaki M, Yokoyama M, Saito Y, Origasa H, Ishikawa Y, Oikawa S et al.. Incremental effects of eicosapentaenoic acid on cardiovascular events in statin-treated patients with coronary artery disease. Circ J. 2009; 73:1283-90.
• [19]Field FJ, Albright EJ, Mathur SN. Effect of dietary n-3 fatty acids on HMG-CoA reductase and ACAT activities in liver and intestine of the rabbit. J Lipid Res. 1987; 28:50-8.
• [20]Das UN. Statins and the prevention of dementia. CMAJ. 2001; 165:908-9.